RareCyte® enables practical deployment of circulating tumor cell-based liquid biopsy with instrumentation and consumables that provide an exquisitely sensitive, accurate, reproducible, and transparent workflow from blood collection to single-cell isolation.
- Unbiased, reproducible, highly sensitive, and specific circulating tumor cell detection
- Scalable, high-capacity platform with workflow breakpoints, including slide banking, that enable multi-site execution
- Deploy through our global contract research organization (CRO) network or in your own lab
- Utilize cancer-specific panels or Developer panels for circulating tumor cell biomarker analysis
- Custom assay and companion diagnostics co-development through our Pharma Programs
RareCyte panels for liquid biopsy analysis include markers used for circulating tumor cell identification and biomarker exploration. Circulating tumor cells are identified as nucleated cells that express CK/EpCAM but not CD45. The breast assay used the RarePlex HER2/ER CTC Panel Kit and the prostate assay used the ARv7 CTC Panel Kit and a Developer Kit for AR. With Developer technology, you can customize your panel with up to two of your own biomarkers.
CyteFinder® HT with 80-slide capacity for clinical research.
Three-day blood stability and option to bank slides before staining enables practical multi-site workflow for clinical research.
Five-cell circulating tumor cell cluster expressing drug target from a clinical research study participant. Cytokeratin (red) / EpCAM (magenta) / Drug target (green) / CD45 (yellow) / nuclei (blue)
Bank AccuCyte slides in freezer prior to staining.
